363 related articles for article (PubMed ID: 33799768)
21. Cutting-Edge CAR Engineering: Beyond T Cells.
Chocarro L; Blanco E; Fernández-Rubio L; Arasanz H; Bocanegra A; Echaide M; Garnica M; Ramos P; Piñeiro-Hermida S; Vera R; Kochan G; Escors D
Biomedicines; 2022 Nov; 10(12):. PubMed ID: 36551788
[TBL] [Abstract][Full Text] [Related]
22. Role of CAR T Cell Metabolism for Therapeutic Efficacy.
Rial Saborido J; Völkl S; Aigner M; Mackensen A; Mougiakakos D
Cancers (Basel); 2022 Nov; 14(21):. PubMed ID: 36358860
[TBL] [Abstract][Full Text] [Related]
23. Crosstalk between autophagy and metabolic regulation of (CAR) T cells: therapeutic implications.
Panahi Meymandi AR; Akbari B; Soltantoyeh T; Hadjati J; Klionsky DJ; Badie B; Mirzaei HR
Front Immunol; 2023; 14():1212695. PubMed ID: 37675121
[TBL] [Abstract][Full Text] [Related]
24. Solid Tumors Challenges and New Insights of CAR T Cell Engineering.
Tahmasebi S; Elahi R; Esmaeilzadeh A
Stem Cell Rev Rep; 2019 Oct; 15(5):619-636. PubMed ID: 31161552
[TBL] [Abstract][Full Text] [Related]
25. Determination of CAR T cell metabolism in an optimized protocol.
Joaquina S; Forcados C; Caulier B; Inderberg EM; Wälchli S
Front Bioeng Biotechnol; 2023; 11():1207576. PubMed ID: 37409169
[TBL] [Abstract][Full Text] [Related]
26. Importance of T, NK, CAR T and CAR NK Cell Metabolic Fitness for Effective Anti-Cancer Therapy: A Continuous Learning Process Allowing the Optimization of T, NK and CAR-Based Anti-Cancer Therapies.
Krug A; Martinez-Turtos A; Verhoeyen E
Cancers (Basel); 2021 Dec; 14(1):. PubMed ID: 35008348
[TBL] [Abstract][Full Text] [Related]
27. Metabolic and epigenetic orchestration of (CAR) T cell fate and function.
Akbari B; Hosseini Z; Shahabinejad P; Ghassemi S; Mirzaei HR; O'Connor RS
Cancer Lett; 2022 Dec; 550():215948. PubMed ID: 36209973
[TBL] [Abstract][Full Text] [Related]
28. T-cell exhaustion in CAR-T-cell therapy and strategies to overcome it.
Yin X; He L; Guo Z
Immunology; 2023 Aug; 169(4):400-411. PubMed ID: 36942414
[TBL] [Abstract][Full Text] [Related]
29. The landscape of chimeric antigen receptor T cell therapy in breast cancer: Perspectives and outlook.
Zhang H; Zhu S; Deng W; Li R; Zhou H; Xiong H
Front Immunol; 2022; 13():887471. PubMed ID: 35935930
[TBL] [Abstract][Full Text] [Related]
30. CAR-T cell combination therapy: the next revolution in cancer treatment.
Al-Haideri M; Tondok SB; Safa SH; Maleki AH; Rostami S; Jalil AT; Al-Gazally ME; Alsaikhan F; Rizaev JA; Mohammad TAM; Tahmasebi S
Cancer Cell Int; 2022 Nov; 22(1):365. PubMed ID: 36419058
[TBL] [Abstract][Full Text] [Related]
31. Improving the ability of CAR-T cells to hit solid tumors: Challenges and strategies.
Zhang ZZ; Wang T; Wang XF; Zhang YQ; Song SX; Ma CQ
Pharmacol Res; 2022 Jan; 175():106036. PubMed ID: 34920118
[TBL] [Abstract][Full Text] [Related]
32. CAR T Cells for Solid Tumors: New Strategies for Finding, Infiltrating, and Surviving in the Tumor Microenvironment.
Martinez M; Moon EK
Front Immunol; 2019; 10():128. PubMed ID: 30804938
[TBL] [Abstract][Full Text] [Related]
33. Potential of chimeric antigen receptor (CAR)-redirected immune cells in breast cancer therapies: Recent advances.
Nikoo M; Rudiansyah M; Bokov DO; Jainakbaev NT; Suksatan W; Ansari MJ; Thangavelu L; Chupradit S; Zamani A; Adili A; Shomali N; Akbari M
J Cell Mol Med; 2022 Aug; 26(15):4137-4156. PubMed ID: 35762299
[TBL] [Abstract][Full Text] [Related]
34. Chimeric antigen receptor engineered T cells and their application in the immunotherapy of solid tumours.
Mao R; Hussein MS; He Y
Expert Rev Mol Med; 2022 Jan; 24():e7. PubMed ID: 35086597
[TBL] [Abstract][Full Text] [Related]
35. Mathematical deconvolution of CAR T-cell proliferation and exhaustion from real-time killing assay data.
Sahoo P; Yang X; Abler D; Maestrini D; Adhikarla V; Frankhouser D; Cho H; Machuca V; Wang D; Barish M; Gutova M; Branciamore S; Brown CE; Rockne RC
J R Soc Interface; 2020 Jan; 17(162):20190734. PubMed ID: 31937234
[TBL] [Abstract][Full Text] [Related]
36. Potential strategies against resistance to CAR T-cell therapy in haematological malignancies.
Cai Q; Zhang M; Li Z
Ther Adv Med Oncol; 2020; 12():1758835920962963. PubMed ID: 33133242
[TBL] [Abstract][Full Text] [Related]
37. Engineering Next-Generation CAR-T Cells: Overcoming Tumor Hypoxia and Metabolism.
Gao TA; Chen YY
Annu Rev Chem Biomol Eng; 2022 Jun; 13():193-216. PubMed ID: 35700528
[TBL] [Abstract][Full Text] [Related]
38. Targeting sphingosine 1-phosphate receptor 3 inhibits T-cell exhaustion and regulates recruitment of proinflammatory macrophages to improve antitumor efficacy of CAR-T cells against solid tumor.
Gao G; Liao W; Shu P; Ma Q; He X; Zhang B; Qin D; Wang Y
J Immunother Cancer; 2023 Aug; 11(8):. PubMed ID: 37591632
[TBL] [Abstract][Full Text] [Related]
39. Modulating tumor physical microenvironment for fueling CAR-T cell therapy.
Luo Z; Yao X; Li M; Fang D; Fei Y; Cheng Z; Xu Y; Zhu B
Adv Drug Deliv Rev; 2022 Jun; 185():114301. PubMed ID: 35439570
[TBL] [Abstract][Full Text] [Related]
40. Chimeric-antigen receptor T (CAR-T) cell therapy for solid tumors: challenges and opportunities.
Xia AL; Wang XC; Lu YJ; Lu XJ; Sun B
Oncotarget; 2017 Oct; 8(52):90521-90531. PubMed ID: 29163850
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
